Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
SD ENTERTAINMENT, Apr-Dec (Cumulative 3Q) Ordinary Profit Turns to Loss, Oct-Dec Ordinary Profit Turns to Loss
4650 SD ENTERTAINMENT,Inc. 【J-GAAP】
Earnings ReportSD ENTERTAINMENT,Inc. <4650> [TSE Std] announced its financial results after the market closed on February 12th (15:30). The consolidated ordinary profit/loss for the cumulative third quarter of the fiscal year ending March 2026 (April to December) turned into a loss of 119 million yen (compared to a profit of 44 million yen in the same period last year).
Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the January to March period (4Q) is expected to surge 9.9 times that of the same period last year, reaching 159 million yen.
In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit/loss turned to a loss of 28 million yen (compared to a profit of 47 million yen in the same period last year). The operating profit/loss margin drastically worsened from 5.4% in the same period last year to -1.4%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Dec, 2023 | 2,725 | 38 | 7 | -16 | -1.8 | 8.5 | Feb 13, 2024 | J-GAAP |
| Apr - Dec, 2024 | 2,968 | 73 | 44 | 5 | 0.6 | 73.3 | Feb 14, 2025 | J-GAAP |
| Apr - Dec, 2025 | 3,670 | -95 | -119 | 18 | 2.1 | ー | Feb 12, 2026 | J-GAAP |
| YoY | +23.7% | - | - | +260.0% | +260.3% |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 2,305 | 83 | 63 | 115 | 13.0 | 0 | May 15, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | 2,690 | 156 | 131 | 276 | 30.8 | - | Nov 13, 2025 | J-GAAP |
| YoY | +16.7% | +88.0% | +107.9% | +140.0% | +137.8% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 3,735 | 122 | 82 | 117 | 13.2 | 0 | May 15, 2024 | J-GAAP |
| Mar, 2025 | 4,201 | 98 | 60 | 93 | 10.5 | 0 | May 15, 2025 | J-GAAP |
| Mar, 2026 Guidance | 5,000 | 80 | 40 | 210 | 23.5 | - | May 15, 2025 | J-GAAP |
| YoY | +19.0% | -18.4% | -33.3% | +125.8% | +123.8% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 1,072 | 58 | 47 | 27 | 3.1 | 5.4 | Feb 14, 2025 | J-GAAP |
| Jan - Mar, 2025 | 1,233 | 25 | 16 | 88 | 9.9 | 2.0 | May 15, 2025 | J-GAAP |
| Apr - Jun, 2025 | 1,108 | -123 | -132 | -108 | -12.1 | -11.1 | Aug 14, 2025 | J-GAAP |
| Jul - Sep, 2025 | 1,202 | 47 | 41 | 42 | 4.7 | 3.9 | Nov 13, 2025 | J-GAAP |
| Oct - Dec, 2025 | 1,360 | -19 | -28 | 84 | 9.8 | -1.4 | Feb 12, 2026 | J-GAAP |
| YoY | +26.9% | - | - | +211.1% | +211.5% |
Related Articles
INPEX, 16% Decrease in Net Income for The Current Fiscal Year, Dividend Raised by 8 Yen
KLab, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.
en Japan, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 12%, Exceeds Full-Year Plan
Fuso Pharma, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 34%, Oct-Dec Ordinary Profit Decreases by 9%
WASHINGTON HOTEL, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 31%, Dividend Revised Upward by 14 Yen
CyberBuzz, Oct-Dec (1Q) Ordinary Profit Increases by 50%
ReproCELL, Ordinary Profit Forecast for the Fiscal Year Loss Widened in Downward Revision
Monex Group, Apr-Dec (Cumulative 3Q) Net Income Turns to Profit, Oct-Dec Net Income Turns to Profit
ROHTO PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 6%, Exceeded Record Profit Forecast, Dividend Revised Upward by 1 Yen
CRI Middleware, Oct-Dec (1Q) Ordinary Profit Decreases by 74%